 Affimed has generated an impressive pipeline of innate cell engagers programs created using their three-pronged development strategy. These programs target high unmet needs and large market opportunities. Affimed recently finalized a 103.5M public offering, which will help fund the companys wholly-owned programs to hit key catalysts over the remainder of 2022 and into 2023. 